WO2016159577A3 - Dérivé de 1,2-naphthoquinone et son procédé de préparation - Google Patents

Dérivé de 1,2-naphthoquinone et son procédé de préparation Download PDF

Info

Publication number
WO2016159577A3
WO2016159577A3 PCT/KR2016/003031 KR2016003031W WO2016159577A3 WO 2016159577 A3 WO2016159577 A3 WO 2016159577A3 KR 2016003031 W KR2016003031 W KR 2016003031W WO 2016159577 A3 WO2016159577 A3 WO 2016159577A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparing same
naphthoquinone derivative
pharmaceutically acceptable
naphthoquinone
derivative
Prior art date
Application number
PCT/KR2016/003031
Other languages
English (en)
Korean (ko)
Other versions
WO2016159577A2 (fr
Inventor
이휘성
이미정
김보정
이강우
노태철
서강식
김진환
민기남
Original Assignee
주식회사 케이티앤지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 케이티앤지생명과학 filed Critical 주식회사 케이티앤지생명과학
Publication of WO2016159577A2 publication Critical patent/WO2016159577A2/fr
Publication of WO2016159577A3 publication Critical patent/WO2016159577A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé représenté par la formule chimique (1) définie dans la revendication 1, et un sel pharmaceutiquement acceptable, un hydrate, un solvate, un promédicament, un tautomère, un énantiomère, ou un de ses diastéréo-isomères pharmaceutiquement acceptables.
PCT/KR2016/003031 2015-03-27 2016-03-25 Dérivé de 1,2-naphthoquinone et son procédé de préparation WO2016159577A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150043050A KR101864426B1 (ko) 2015-03-27 2015-03-27 1,2 나프토퀴논 유도체 및 이의 제조방법
KR10-2015-0043050 2015-03-27

Publications (2)

Publication Number Publication Date
WO2016159577A2 WO2016159577A2 (fr) 2016-10-06
WO2016159577A3 true WO2016159577A3 (fr) 2017-01-05

Family

ID=57006968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003031 WO2016159577A2 (fr) 2015-03-27 2016-03-25 Dérivé de 1,2-naphthoquinone et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR101864426B1 (fr)
WO (1) WO2016159577A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118119A (ko) 2018-04-09 2019-10-17 주식회사 휴엔 1,2-나프토퀴논 유도체 화합물을 포함하는 고형암 또는 혈액암의 예방 또는 치료용 약학 조성물
US11684610B2 (en) 2018-04-09 2023-06-27 Yungjin Pharm. Co., Ltd. Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
KR101952581B1 (ko) * 2018-11-21 2019-02-27 한양대학교 산학협력단 다공성 구조체의 제조방법
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
KR102247694B1 (ko) 2019-05-31 2021-05-03 주식회사 엘마이토테라퓨틱스 나프토퀴논 또는 벤조인다졸 화합물을 유효성분으로 포함하는 염증성 질환 치료용 약학적 조성물
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
KR20220099970A (ko) 2019-10-11 2022-07-14 인사이트 코포레이션 Cdk2 억제제로서의 이환식 아민
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611056A (en) * 1983-10-05 1986-09-09 Merck Frosst Canada, Inc. Benzo[A]phenothiazines and hydro-derivatives
US5283330A (en) * 1992-09-11 1994-02-01 Bhansali Kantilal G 1,2-benzo-8-(D,L alanyl)-3-phenoxazone nitrate
WO2007079801A1 (fr) * 2005-12-23 2007-07-19 Henkel Ag & Co. Kgaa Nouveaux constituants coupleurs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611056A (en) * 1983-10-05 1986-09-09 Merck Frosst Canada, Inc. Benzo[A]phenothiazines and hydro-derivatives
US5283330A (en) * 1992-09-11 1994-02-01 Bhansali Kantilal G 1,2-benzo-8-(D,L alanyl)-3-phenoxazone nitrate
WO2007079801A1 (fr) * 2005-12-23 2007-07-19 Henkel Ag & Co. Kgaa Nouveaux constituants coupleurs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Chemical Abstract 29 March 1986 (1986-03-29), retrieved from STN Database accession no. 10 063-87 -0 *
DE TOLEDO, J. S. ET AL.: "Synthesis, Cytotoxicity and in Vitro Antileishmanial Activity of Naphthothiaxotes''.", CHEM. BIOL. DRUG DES., vol. 81, no. 6, 2013, pages 749 - 756, XP028312457 *

Also Published As

Publication number Publication date
KR101864426B1 (ko) 2018-06-05
WO2016159577A2 (fr) 2016-10-06
KR20160116211A (ko) 2016-10-07

Similar Documents

Publication Publication Date Title
WO2016159577A3 (fr) Dérivé de 1,2-naphthoquinone et son procédé de préparation
EP3459925A4 (fr) Procédé de préparation de dérivé de benzaldéhyde 2-hydroxyl-4-(benzyloxy 2,3-disubstitué)-5-substitué
LT3577110T (lt) 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai
WO2016011390A8 (fr) Agents d'inhibition de l'irak 4
WO2016159576A3 (fr) Dérivé de 1,2-naphthoquinone et son procédé de préparation
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
HUE052796T2 (hu) Eljárás 4-ammónium-2,2,6,6-tetraalkilpiperidinil-sók elõállítására
MY194116A (en) Pharmaceutical compounds
EP3480198A4 (fr) Nouveau composé ou son sel pharmaceutiquement accepté
WO2015142903A3 (fr) Procédé pour réguler la production de lactate à l'aide de dérivés de pipéridine-dione
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
EP3617185A4 (fr) Procédé de production d'un composé amide
WO2016125191A3 (fr) Procédés de préparation de bromhydrate de vortioxétine
WO2015000431A9 (fr) Carbamate de tizoxanide et son utilisation pharmaceutique
WO2015068175A3 (fr) Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
EP3315492A4 (fr) Dérivé de pyrazole, ou son sel pharmaceutiquement acceptable
IL262534B (en) A method for the production of 5-hydroxyalkyl substituted 1-phenyl-4,2,1-triazole derivatives
WO2015181802A3 (fr) Composition pharmaceutique orale d'isotrétinoïne
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.
PL3484855T3 (pl) Nowy związek benzyloamidowy, sposób jego wytwarzania i środek roztoczobójczy
WO2015191681A3 (fr) Pyridinones substituées utilisées comme inhibiteurs de mgat2
WO2016027283A3 (fr) Procédé de préparation de d'indacatérol et de sels de celui-ci
WO2015199418A3 (fr) Nouveau composé hétérocyclique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16773358

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16773358

Country of ref document: EP

Kind code of ref document: A2